Clinical Trial Update: Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents [Phase 2]

View source ↗

Summary

Phase 2 trial results for lenalidomide in myelodysplastic syndromes refractory to hypomethylating agents; the study is completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2016-01-05